Latest Health News

Bioxyne Limited has delivered a record-breaking second quarter in FY2026, posting $17.2 million in revenue and expanding its footprint into key international markets. The company’s growth is underpinned by new contracts, innovative psychedelics products, and strategic government funding.

Anagenics Limited reports a significant turnaround with profitable trading in the second quarter of FY26, driven by strong brand performance and a successful capital raise. The company is poised for growth with expanding product lines and international ambitions.

Aerometrex Limited has reported record first half revenue and EBITDA for the six months ending December 2025, driven by strong MetroMap subscription growth and a rebound in LiDAR sales.

Starpharma reports strong progress in strategic collaborations and internal drug development, alongside a 70% surge in Viraleze™ online sales and a solid $18.2 million cash position.

Titan Minerals secures a strategic $10 million investment from Lingbao Gold International, advancing its Dynasty Gold and Linderos Copper projects with promising drilling results and a strong cash position.

Vitura Health has announced the departure of CEO Geoff Cockerill, appointing Chief Revenue Officer Ryan Tattle as interim leader while accelerating the search for a new CEO. Incoming CFO Andrew Cook will join ahead of schedule, signalling a renewed focus on operational and financial discipline.

Nickel Industries reported a 57% drop in quarterly EBITDA due to mining quota delays but showcased robust HPAL margins and advanced commissioning at its Excelsior project, supported by a strategic investment from Sphere Corp.

Strike Energy reports steady progress on its South Erregulla gas power project, while optimising Walyering production and maintaining strong liquidity. The company navigates market conditions with a strategic reduction in output and plans for upcoming drilling activities.

Spacetalk Ltd has completed a major pivot from hardware to a scalable software-as-a-service model, driving a 26% increase in active mobile subscribers and a 9% rise in annual recurring revenue to $12 million.

Mayne Pharma delivered a robust FY25 performance with a 105% surge in underlying EBITDA and launched key dermatology products as it outlines a strategic growth path for FY26.

Appen Limited delivered a robust Q4 FY25, driven by explosive growth in its China segment and strong gains in generative AI projects globally, boosting revenue and profitability significantly.

Image Resources NL reported a strong finish to 2025 with record heavy mineral concentrate production and sales, alongside promising developments in its gold exploration and synthetic rutile innovation.